Skip to main content

Diagnosing Idiopathic Pulmonary Fibrosis: Education for the Community-based Radiologist

Step 1: 
Click here to "sign-up."
If you have already signed up and are logged in, proceed to Step 3.
Step 2: Click on the IPF webinar course to return to this page. 
Step 3: 
Click here to complete the pre-activity survey.
Step 4: Click the register button once the pre-activity survey is complete. 

Monday, October 8, 2018
8:00 – 9:00 PM EST (7:00 - 8:00 PM CST / 5:00 – 6:00 PM PST)

Welcome, Introductions, and Pre-survey
Interpreting HRCT: How to Identify IPF and Other ILDs
Role of Community Radiologists in IPF Diagnosis and Monitoring
Concluding Remarks and Q&A

Patients with idiopathic pulmonary fibrosis (IPF) continue to suffer unacceptable delays in diagnoses and initiation of optimal treatments that can positively impact morbidity and mortality. Radiologists play a critical role in the accurate interpretation of high-resolution computed tomography (HRCT) scans and are essential in identifying candidates for agents approved for the treatment of IPF. Because more than 80% of referring physicians rely on radiologists’ interpretations of CT scans all or most of the time, it is essential that radiologists are aware of the clinical features and distinct radiology pattern of IPF and are able to distinguish IPF from other idiopathic interstitial pneumonias (IIPs) and lung-disease patients.

Stephen Hobbs, MD

Assistant Professor of Radiology and Medicine
Division of Cardiovascular and Thoracic Radiology
Medical Director, UK HealthCare Imaging Informatics
University of Kentucky
Lexington, KY

Stephen Hobbs, MD
serves as a cardiothoracic radiologist in the Department of Radiology at the University of Kentucky. He has lectured at the national and international level on thoracic-imaging topics ranging from thoracic surgery complications to diffuse pulmonary nodule patterns. Dr. Hobbs has particular interests in interstitial lung disease, as well as in resident education, and is Co‐editor of the recently released Thoracic Imaging: A Core Review. He serves as the Imaging Informatics Medical Director for both the Department of Radiology and the entire UK HealthCare Enterprise. He completed a radiology residency at the University of Kentucky and subspecialty fellowship training in cardiothoracic radiology at the University of Colorado and National Jewish Health in Denver, CO.

Chris Lee, MD
Associate Professor of Clinical Radiology
Cardiothoracic Imaging and Intervention Fellowship Director
Thoracic Interventional Services
Keck School of Medicine of USC
Los Angeles, CA

Chris Lee, MD is a cardiothoracic radiologist and Associate Professor of Clinical Radiology at the Keck School of Medicine of the University of Southern California (USC). He is Director of the Cardiothoracic Imaging and Intervention Fellowship at USC and Director of the USC Lung Cancer Screening Program. Dr. Lee’s research and academic interests include lung cancer screening, interstitial lung disease, thoracic interventions, and advanced cardiac imaging with CT/MRI. He has presented at numerous local, national, and international conferences, and he has authored many publications pertaining to his interests. A native of California, Dr. Lee received both his undergraduate and medical training at the University of California Los Angeles (UCLA). Dr. Lee remained at UCLA for both his diagnostic radiology residency and thoracic imaging fellowship before moving across town to become a faculty member at Keck Medicine of USC.

This activity is intended for community radiologists and radiologic technologists involved in the diagnosis of lung disease.

At the conclusion of this activity, participants should be able to demonstrate the ability to:

  • Recognize the clinical features of IPF, including pulmonary and non-pulmonary findings in HRCT images and patient history 
  • Distinguish IPF from other pulmonary conditions by differentiating usual interstitial pneumonia (UIP) categories (definite, possible, and inconsistent) in HRCT images 
  • Effectively communicate with referring physicians regarding HRCT results and diagnoses of IPF 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Potomac Center for Medical Education designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

For questions regarding CME credit or the evaluation, please email

Approved by the ASRT for Category A continuing education credit. Radiologic technologists will receive 1.0 credit for completion of the activity.

Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.

Faculty Disclosures
The faculty and steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Stephen Hobbs, MD: Nothing to disclose
Chris Lee, MD: Nothing to disclose

Non-faculty Content Contributors
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Chad Williamson, MS, MBA, CMPP; Jeanelle Spencer, PhD; Blair St. Amand; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, MBA, MSN, RN; Jan Schultz, MSN, RN, FACEHP, CHCP; Lindsay Scott, PT, DPT, ATC: Nothing to disclose

FDA Disclosure
The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of  approved uses.

To ensure your computer is compatible for the live event, please perform a system check by clicking on the link or by typing it into your internet browser. Please perform the system check on the same computer you will use for the live event. If your computer is compatible, you will receive a confirmation message on your screen and hear audio. Otherwise, please contact the Help Desk to resolve any issues.

There is no fee for this activity. To receive credit, participants must answer the pre-activity survey questions during registration, view this CME/CE activity in its entirety, and then complete the post-test, with a score of 75% or better, and evaluation. The estimated time for completion of this activity is 1 hour. To receive a certificate, participants must demonstrate mastery of the presented material via the module post-test. Participant is allowed to take the post-test 3 times.

If you will be watching the webinar in a group setting, please note all group participants will need to register individually in order to complete the post-test and evaluation to receive credit.

Jointly provided by Potomac Center for Medical Education, Postgraduate Institute for Medicine, and Rockpointe

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.